225 related articles for article (PubMed ID: 33869018)
1. Algorithm-Based Meta-Analysis Reveals the Mechanistic Interaction of the Tumor Suppressor LIMD1 With Non-Small-Cell Lung Carcinoma.
Wang L; Sparks-Wallace A; Casteel JL; Howell MEA; Ning S
Front Oncol; 2021; 11():632638. PubMed ID: 33869018
[TBL] [Abstract][Full Text] [Related]
2. LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC.
Liu T; Xu S; Liu X
Oncol Lett; 2022 Feb; 23(2):55. PubMed ID: 34992687
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Profiling of Genomic and Transcriptomic Differences between Risk Groups of Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Zengin T; Önal-Süzek T
J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672117
[TBL] [Abstract][Full Text] [Related]
4. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
[TBL] [Abstract][Full Text] [Related]
6. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
7. The Effect of GLUT1 on the Survival Rate and Immune Cell Infiltration of Lung Adenocarcinoma and Squamous Cell Carcinoma: A Meta and Bioinformatics Analysis.
Zhang G; Dong R; Kong D; Liu B; Zha Y; Luo M
Anticancer Agents Med Chem; 2022; 22(2):223-238. PubMed ID: 34238200
[TBL] [Abstract][Full Text] [Related]
8. LIMD1-AS1 suppressed non-small cell lung cancer progression through stabilizing LIMD1 mRNA via hnRNP U.
Pan J; Tang Y; Liu S; Li L; Yu B; Lu Y; Wang Y
Cancer Med; 2020 Jun; 9(11):3829-3839. PubMed ID: 32239804
[TBL] [Abstract][Full Text] [Related]
9. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G; Lu Z; Bi Y; Deng J; Yang X
Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
[TBL] [Abstract][Full Text] [Related]
10. Transcriptome analysis of distinct long non-coding RNA transcriptional fingerprints in lung adenocarcinoma and squamous cell carcinoma.
Wei Y; Zhang X
Tumour Biol; 2016 Oct; ():. PubMed ID: 27797003
[TBL] [Abstract][Full Text] [Related]
11. Validation and analysis of expression, prognosis and immune infiltration of WNT gene family in non-small cell lung cancer.
Wang J; Yang Q; Tang M; Liu W
Front Oncol; 2022; 12():911316. PubMed ID: 35957916
[TBL] [Abstract][Full Text] [Related]
12. Shared network pattern of lung squamous carcinoma and adenocarcinoma illuminates therapeutic targets for non-small cell lung cancer.
Li P; Kuang X; Zhang T; Ma L
Front Surg; 2022; 9():958479. PubMed ID: 36263088
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of Immune Implication and Prognostic Value of
Zeng Y; Zhang Z; Chen H; Fan J; Yuan W; Li J; Zhou S; Liu W
Front Oncol; 2021; 11():798425. PubMed ID: 35047409
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.
Schlensog M; Magnus L; Heide T; Eschenbruch J; Steib F; Tator M; Kloten V; Rose M; Noetzel E; Gaisa NT; Knüchel R; Dahl E
Epigenetics; 2018; 13(3):214-227. PubMed ID: 27623992
[TBL] [Abstract][Full Text] [Related]
15. Tumor Suppressor 4.1N/
Yang Q; Zhu L; Ye M; Zhang B; Zhan P; Li H; Zou W; Liu J
Front Genet; 2022; 13():805960. PubMed ID: 35795202
[TBL] [Abstract][Full Text] [Related]
16. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
Zhou S; Wang P; Su X; Chen J; Chen H; Yang H; Fang A; Xie L; Yao Y; Yang J
PLoS One; 2017; 12(10):e0187356. PubMed ID: 29088286
[TBL] [Abstract][Full Text] [Related]
17. Expression, Prognosis and Gene Regulation Network of NFAT Transcription Factors in Non-Small Cell Lung Cancer.
Ma J; Du R; Huang Y; Zhong W; Gui H; Mao C; Song X; Lu J
Pathol Oncol Res; 2021; 27():529240. PubMed ID: 34257525
[TBL] [Abstract][Full Text] [Related]
18. Skp2 expression has different clinicopathological and prognostic implications in lung adenocarcinoma and squamous cell carcinoma.
Zhong K; Yang F; Han Q; Chen J; Wang J
Oncol Lett; 2018 Sep; 16(3):2873-2880. PubMed ID: 30127874
[TBL] [Abstract][Full Text] [Related]
19. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
Yu H; Pang Z; Li G; Gu T
J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
[TBL] [Abstract][Full Text] [Related]
20. Genomic landscape and prognosis of patients with
Fan Z; Zhang Q; Feng L; Wang L; Zhou X; Han J; Li D; Liu J; Zhang X; Zuo J; Zou X; Cai Y; Sun Y; Wang Y
Ann Transl Med; 2022 Feb; 10(4):188. PubMed ID: 35280362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]